Foresite Capital Management III as of Dec. 31, 2016
Portfolio Holdings for Foresite Capital Management III
Foresite Capital Management III holds 20 positions in its portfolio as reported in the December 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | 26.3 | $61M | 1.6M | 37.85 | |
| Achaogen | 14.8 | $34M | 2.6M | 13.02 | |
| Alder Biopharmaceuticals | 14.7 | $34M | 1.6M | 20.80 | |
| Aimmune Therapeutics | 8.0 | $19M | 904k | 20.45 | |
| Wave Life Sciences (WVE) | 7.7 | $18M | 676k | 26.15 | |
| Nanostring Technologies (NSTGQ) | 4.2 | $9.8M | 438k | 22.30 | |
| Intellia Therapeutics (NTLA) | 4.0 | $9.2M | 704k | 13.11 | |
| Blueprint Medicines (BPMC) | 3.7 | $8.4M | 300k | 28.05 | |
| Protagonist Therapeutics (PTGX) | 3.3 | $7.6M | 346k | 21.99 | |
| Epizyme | 3.2 | $7.3M | 605k | 12.10 | |
| Irhythm Technologies (IRTC) | 2.2 | $5.0M | 166k | 30.00 | |
| Editas Medicine (EDIT) | 1.9 | $4.5M | 275k | 16.23 | |
| Aclaris Therapeutics (ACRS) | 1.8 | $4.2M | 156k | 27.14 | |
| Ascendis Pharma A S (ASND) | 1.6 | $3.6M | 180k | 20.24 | |
| Zafgen | 0.7 | $1.5M | 469k | 3.18 | |
| Akari Therapeutics | 0.6 | $1.4M | 197k | 7.04 | |
| Audentes Therapeutics | 0.5 | $1.2M | 67k | 18.27 | |
| Global Blood Therapeutics In | 0.4 | $919k | 64k | 14.44 | |
| Acceleron Pharma | 0.2 | $507k | 20k | 25.50 | |
| Orexigen Therapeutics | 0.2 | $442k | 254k | 1.74 |
